A drug called donanemab has shown promise for treating Alzheimer’s disease. It was tested in a global study and found to slow down memory decline in people with early-stage Alzheimer’s by targeting protein buildup in the brain. While it’s not a cure, the results are hopeful. The UK’s National Institute for Health and Care Excellence (NICE) is considering using donanemab in the National Health Service (NHS). The drug has been shown to slow disease progression by about one-third, helping patients maintain their daily activities and quality of life. However, there are risks, such as brain swelling, which was seen in the study. Despite the risks, donanemab represents progress in fighting Alzheimer’s and brings hope to those affected by the disease.

Efforts are also being made to diagnose Alzheimer’s earlier and prepare the NHS for providing the necessary treatments. The results of the donanemab study are a step forward in the battle against Alzheimer’s and offer hope to millions of people affected by the disease.